(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...
The Daily Overview on MSN
How safe is Pfizer's dividend as 2026 begins?
Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...
Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...
Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...
Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost ...
68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results